

S 2740

PREPARE Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Sep 14, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sep 14, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/2740>

Sponsor

Name: Sen. Brown, Sherrod [D-OH]

Party: Democratic • **State:** OH • **Chamber:** Senate

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Cassidy, Bill [R-LA]	R · LA		Sep 14, 2021
Sen. Blackburn, Marsha [R-TN]	R · TN		Oct 18, 2021
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Oct 18, 2021
Sen. Capito, Shelley Moore [R-WV]	R · WV		Oct 25, 2021
Sen. Kaine, Tim [D-VA]	D · VA		Oct 25, 2021
Sen. Warner, Mark R. [D-VA]	D · VA		Dec 8, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Sep 14, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 5388	Related bill	Sep 28, 2021: Referred to the Subcommittee on Health.

Promoting Readiness and Ensuring Proper Active pharmaceutical ingredient Reserves of Essential medicines Act of 2021 or the PREPARE Act

This bill establishes the Strategic Active Pharmaceutical Ingredient Reserve.

The Department of Health and Human Services (HHS) must annually publish a public list of essential generic medicines that are medically necessary to have available at all times.

HHS must report and implement a plan to establish the reserve, which must be designed to minimize the impact of an interruption or reduction in imports of (1) key starting materials (including active pharmaceutical ingredients) for essential generic medicines, and (2) finished dosage forms of essential generic medicines for which key starting materials are not imported. The plan must also contain provisions to strengthen domestic capacity for active pharmaceutical ingredient production, storage, and conversion.

Within one year of this bill's enactment, the plan must include at least 25 of the essential generic medicines on the required list. The plan must add at least 25 medicines each year until the full list is covered.

HHS must prioritize domestically manufactured key starting materials for the reserve to the maximum extent possible.

A manufacturer of an essential generic medicine that switches to an active pharmaceutical ingredient sourced through the reserve shall not have to update the approved application for that medicine.

The Government Accountability Office must report to Congress on active pharmaceutical ingredient manufacturing, including the time and costs needed to develop domestic manufacturing capabilities.

Actions Timeline

- **Sep 14, 2021:** Introduced in Senate
- **Sep 14, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.